325 related articles for article (PubMed ID: 11756773)
21. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA
Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977
[TBL] [Abstract][Full Text] [Related]
22. Microphthalmia transcription factor: a sensitive and specific marker for malignant melanoma in cytologic specimens.
Dorvault CC; Weilbaecher KN; Yee H; Fisher DE; Chiriboga LA; Xu Y; Chhieng DC
Cancer; 2001 Oct; 93(5):337-43. PubMed ID: 11668469
[TBL] [Abstract][Full Text] [Related]
23. A metastatic melanoma with an unusual immunophenotypic profile.
Gao Z; Stanek A; Chen S
Am J Dermatopathol; 2007 Apr; 29(2):169-71. PubMed ID: 17414440
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical evaluation of necrotic malignant melanomas.
Nonaka D; Laser J; Tucker R; Melamed J
Am J Clin Pathol; 2007 May; 127(5):787-91. PubMed ID: 17439838
[TBL] [Abstract][Full Text] [Related]
25. The correlation of TRPM1 (Melastatin) mRNA expression with microphthalmia-associated transcription factor (MITF) and other melanogenesis-related proteins in normal and pathological skin, hair follicles and melanocytic nevi.
Lu S; Slominski A; Yang SE; Sheehan C; Ross J; Carlson JA
J Cutan Pathol; 2010 Apr; 37 Suppl 1(Suppl 1):26-40. PubMed ID: 20482673
[TBL] [Abstract][Full Text] [Related]
26. Value of melanocytic-associated immunohistochemical markers in the diagnosis of malignant melanoma: a review and update.
Ordóñez NG
Hum Pathol; 2014 Feb; 45(2):191-205. PubMed ID: 23648379
[TBL] [Abstract][Full Text] [Related]
27. Expression of Melan-A and Ki-67 in desmoplastic melanoma and desmoplastic nevi.
Kucher C; Zhang PJ; Pasha T; Elenitsas R; Wu H; Ming ME; Elder DE; Xu X
Am J Dermatopathol; 2004 Dec; 26(6):452-7. PubMed ID: 15618925
[TBL] [Abstract][Full Text] [Related]
28. Micropthalmia transcription factor (MITF) as a diagnostic marker for metastatic melanomas negative for other melanoma markers.
Guo R; Franco-Palacios M; Russell M; Goddard L; Hassell L; Gillies E; Fung KM
Int J Clin Exp Pathol; 2013; 6(8):1658-64. PubMed ID: 23923085
[TBL] [Abstract][Full Text] [Related]
29. Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis.
El Shabrawi-Caelen L; Kerl H; Cerroni L
Am J Dermatopathol; 2004 Oct; 26(5):364-6. PubMed ID: 15365366
[TBL] [Abstract][Full Text] [Related]
30. Aberrant intermediate filament and synaptophysin expression is a frequent event in malignant melanoma: an immunohistochemical study of 73 cases.
Romano RC; Carter JM; Folpe AL
Mod Pathol; 2015 Aug; 28(8):1033-42. PubMed ID: 26022451
[TBL] [Abstract][Full Text] [Related]
31. p75 nerve growth factor receptor staining helps identify desmoplastic and neurotropic melanoma.
Kanik AB; Yaar M; Bhawan J
J Cutan Pathol; 1996 Jun; 23(3):205-10. PubMed ID: 8793654
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical analysis of novel monoclonal antibody PNL2 and comparison with other melanocyte differentiation markers.
Busam KJ; Kucukgöl D; Sato E; Frosina D; Teruya-Feldstein J; Jungbluth AA
Am J Surg Pathol; 2005 Mar; 29(3):400-6. PubMed ID: 15725810
[TBL] [Abstract][Full Text] [Related]
33. Expression of Melan-A in cutaneous granular cell tumours: a diagnostic pitfall.
Van Winden VI; Wong DD; Wood BA; Filion P; Harvey NT
Pathology; 2024 Feb; 56(1):47-51. PubMed ID: 37989630
[TBL] [Abstract][Full Text] [Related]
34. High prevalence of MiTF staining in undifferentiated pleomorphic sarcoma: caution in the use of melanocytic markers in sarcoma.
Choy B; Hyjek E; Montag AG; Pytel P; Haydon R; Luu HH; Zhen CJ; Long BC; Kadri S; Segal JP; Furtado LV; Cipriani NA
Histopathology; 2017 Apr; 70(5):734-745. PubMed ID: 27926791
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical distinction of epithelioid histiocytic proliferations from epithelioid melanocytic nevi.
Busam KJ; Granter SR; Iversen K; Jungbluth AA
Am J Dermatopathol; 2000 Jun; 22(3):237-41. PubMed ID: 10871066
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical identification of canine melanocytic neoplasms with antibodies to melanocytic antigen PNL2 and tyrosinase: comparison with Melan A.
Ramos-Vara JA; Miller MA
Vet Pathol; 2011 Mar; 48(2):443-50. PubMed ID: 20858741
[TBL] [Abstract][Full Text] [Related]
37. Melanoma markers in angiomyolipoma of the liver and kidney: a comparative study.
Makhlouf HR; Ishak KG; Shekar R; Sesterhenn IA; Young DY; Fanburg-Smith JC
Arch Pathol Lab Med; 2002 Jan; 126(1):49-55. PubMed ID: 11800647
[TBL] [Abstract][Full Text] [Related]
38. Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma.
Granter SR; Weilbaecher KN; Quigley C; Fisher DE
Appl Immunohistochem Mol Morphol; 2002 Mar; 10(1):47-51. PubMed ID: 11893035
[TBL] [Abstract][Full Text] [Related]
39. Desmoplastic melanoma: comparison of expression of differentiation antigens and cancer testis antigens.
Lim E; Browning J; MacGregor D; Davis ID; Cebon JS
Melanoma Res; 2006 Aug; 16(4):347-55. PubMed ID: 16845331
[TBL] [Abstract][Full Text] [Related]
40. Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells.
Schrader AJ; Probst-Kepper M; Grosse J; Kunter U; Schenk F; Franzke A; Atzpodien J; Buer J
Melanoma Res; 2000 Aug; 10(4):355-62. PubMed ID: 10985670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
